Cardiovascular Systems, Inc. (CSII) Shares Bought by Gabelli Funds LLC

Gabelli Funds LLC boosted its position in Cardiovascular Systems, Inc. (NASDAQ:CSII) by 0.8% in the 1st quarter, HoldingsChannel reports. The firm owned 240,000 shares of the medical device company’s stock after buying an additional 2,000 shares during the period. Gabelli Funds LLC’s holdings in Cardiovascular Systems were worth $5,263,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Alambic Investment Management L.P. increased its stake in Cardiovascular Systems by 39.3% in the 1st quarter. Alambic Investment Management L.P. now owns 23,652 shares of the medical device company’s stock valued at $519,000 after purchasing an additional 6,667 shares in the last quarter. First Mercantile Trust Co. increased its position in Cardiovascular Systems by 95.2% during the first quarter. First Mercantile Trust Co. now owns 12,751 shares of the medical device company’s stock worth $280,000 after buying an additional 6,218 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Cardiovascular Systems by 1.3% during the first quarter. Thrivent Financial for Lutherans now owns 155,138 shares of the medical device company’s stock worth $3,402,000 after buying an additional 2,022 shares in the last quarter. Swiss National Bank increased its position in Cardiovascular Systems by 5.5% during the first quarter. Swiss National Bank now owns 57,800 shares of the medical device company’s stock worth $1,268,000 after buying an additional 3,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Cardiovascular Systems during the first quarter worth $126,000. 80.97% of the stock is owned by hedge funds and other institutional investors.

Get Cardiovascular Systems alerts:

Several equities analysts have weighed in on CSII shares. BidaskClub downgraded Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Tuesday, April 3rd. ValuEngine raised Cardiovascular Systems from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 3rd. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a research report on Thursday, May 3rd. Leerink Swann dropped their price target on Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Finally, Zacks Investment Research raised Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $27.00.

Shares of NASDAQ:CSII opened at $30.64 on Tuesday. The firm has a market capitalization of $1.02 billion, a PE ratio of 1,021.33 and a beta of 2.18. The company has a quick ratio of 3.99, a current ratio of 4.46 and a debt-to-equity ratio of 0.17. Cardiovascular Systems, Inc. has a 52 week low of $20.58 and a 52 week high of $33.11.

Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings data on Wednesday, May 2nd. The medical device company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. The business had revenue of $55.59 million during the quarter, compared to the consensus estimate of $55.63 million. Cardiovascular Systems had a negative return on equity of 1.03% and a negative net margin of 0.59%.

About Cardiovascular Systems

Cardiovascular Systems, Inc, a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSII).

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Leave a Reply

Your email address will not be published. Required fields are marked *